PGG glucan(PGG glucan) - 药物靶点：CD11b x CD32A_在研适应症：乳腺癌_专利_临床

概要

基本信息

药物类型

聚合物

别名

Betafectin、Imprime、Imprime PGG

+ [4]

靶点

CD11b x CD32A

作用方式

激活剂、刺激剂

作用机制

CD11b激活剂(integrin subunit alpha M activators)、CD32A激活剂(低亲和力免疫球蛋白γFc区受体II-a激活剂)、免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

乳腺癌

非在研适应症

晚期非小细胞肺癌KRAS 野生型结直肠癌皮肤黑色素瘤+ [4]

原研机构

Biothera Pharmaceuticals, Inc. (Delaware)

在研机构

HiberCell, Inc.

非在研机构-

权益机构

HiberCell, Inc.

AstraZeneca PLC

Biodesix, Inc.

+ [1]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

18

项与 PGG glucan 相关的临床试验

NCT05484011

/ Terminated临床1期

P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy.
Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

开始日期2022-12-15

申办/合作机构

HiberCell, Inc.

[+1]

NCT05159778

/ Completed临床2期

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled.
The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.

开始日期2021-11-09

申办/合作机构

HiberCell, Inc.

[+1]

CTRI/2021/10/037380

/ Not yet recruiting临床3期

An Open Label, Prospective, Randomized, Comparative, Multiple Arm Clinical Study to Evaluate the Immunomodulatory Efficacy of Nichi Glucan in Comparison with Conventional Therapeutic Regimen in Adult Subjects with Covid-19 caused by SARS-COV2 (B-COV)

开始日期2021-10-25

申办/合作机构-

100 项与 PGG glucan 相关的临床结果

登录后查看更多信息

100 项与 PGG glucan 相关的转化医学

登录后查看更多信息

100 项与 PGG glucan 相关的专利（医药）

登录后查看更多信息

21

项与 PGG glucan 相关的文献（医药）

2024-11-01·Translational Lung Cancer Research

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017

Article

作者: Furqan, Muhammad ; Liu, Li ; Malhotra, Jyoti ; Feldman, Lawrence ; Hulbert, Alicia ; Shergill, Ardaman ; Mott, Sarah L ; Kennedy, Kathleen ; Pasquinelli, Mary M

Background:

Therapeutic strategies to engage anti-tumor innate immunity are still underdeveloped. Imprime PGG (imprime), a pathogen-associated molecular pattern (PAMP), through pattern recognition receptors, successfully illicit a broad-based innate immune response in preclinical models against various cancers. We aimed to study safety and efficacy of imprime in combination with pembrolizumab in advanced stage non-small cell lung cancer (NSCLC).

Methods:

We conducted an investigator-initiated, multi-institutional, single-arm, phase Ib/II trial in previously treated, advanced stage NSCLC patients. Primary endpoints were maximum-tolerated dose (MTD) of imprime for the phase Ib, and progression-free survival (PFS) for the phase II study (NCT03003468).

Results:

All 33 eligible patients were included in the safety analysis. No dose-limiting toxicity was observed and the imprime dose of 4 mg/kg was determined as the MTD. Thirty patients treated at the MTD (phase Ib, 6; phase II, 24) were included in the efficacy analysis. Median length of follow-up was 10.8 months. Confirmed objective response rate was 10% [95% confidence interval (CI): 2-27%], with one complete and two partial responses. Median PFS was 2.6 months (95% CI: 1.4-7.0), and 6- and 12-month PFS rates were 37% and 17%, respectively. Median overall survival (OS) was 11.1 months, and 6- and 12-month OS rates were 75% and 46%. Univariate analysis was performed to assess the impact of age, sex, race, disease-stage, programmed death-ligand 1 (PD-L1) expression levels, and prior immunotherapy on PFS and OS. Of these, prior immunotherapy negatively influenced OS [hazard ratio (HR): 2.95, 95% CI: 1.21-7.24]. Overall, the combination was safe and tolerable.

Conclusions:

The combination of imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage NSCLC patients who previously progressed on anti-programmed death 1 (PD-1)/PD-L1 immunotherapies. Further investigation is needed to understand the effects of therapeutic PAMPs to mount a strong innate immune response against cancer.

2020-03-01·Anticancer research4区 · 医学

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

4区 · 医学

Article

作者: Jha, Gautam ; Qiu, Xiaohong ; Gorden, Keith ; Hurley, Peter J ; Gargano, Michele ; Bose, Nandita ; Ottoson, Nadine ; Rathmann, Blaine ; Harrison, Ben ; Dudek, Arkadiusz Z

BACKGROUND:

BTH1677 is a beta-glucan pathogen-associated molecular pattern (PAMP) being evaluated as a novel immunotherapy of cancer. We previously described that the presence of antibodies against beta-glucan (ABA) in serum is necessary for BTH1677 antitumoral activity. We hypothesized that infusion of immunoglobulin can reinstate responses to BTH1677 in individuals with low ABA levels.

PATIENTS AND METHODS:

We report two single-patient studies: one in a patient with metastatic colorectal cancer who received BTH1677, combined with tumor targeting antibody cetuximab; and a second in a patient with metastatic neuroendocrine tumor who received BTH1677 combined with immune checkpoint inhibitor pembrolizumab.

RESULTS:

The patients had low serum titers of ABA and low innate immune effector functionality induced by BTH1677. Addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoral activity, with long-term disease control.

CONCLUSION:

Infusion of immunoglobulin can restore activity of BTH1677 in individuals with low serum ABA level.

2019-05-15·Journal of immunology (Baltimore, Md. : 1950)2区 · 医学

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

2区 · 医学

Article

作者: Harrison, Ben ; Fulton, Ross B ; Bose, Nandita ; Jordan, Lindsay R ; Fraser, Kathryn A ; Ottoson, Nadine R ; Graff, Jeremy R ; Qiu, Xiaohong ; Ertelt, Kathleen E ; Gorden, Keith B ; Jonas, Adria Bykowski ; Uhlik, Mark T ; Kangas, Takashi O ; Chan, Anissa S H ; Matson, Mark A ; Huhn, Richard D ; Leonardo, Steven M ; Lowe, Jamie R ; Walsh, Richard M ; Rathmann, Blaine T

Abstract:

Imprime PGG (Imprime) is an i.v. administered, yeast β-1,3/1,6 glucan in clinical development with checkpoint inhibitors. Imprime-mediated innate immune activation requires immune complex formation with naturally occurring IgG anti-β glucan Abs (ABA). We administered Imprime to healthy human volunteers to assess the necessity of ABA for Imprime-mediated immunopharmacodynamic (IPD) changes. Imprime (4 mg/kg) was administered i.v. in single and multiple infusions. Subsets of subjects were premedicated with antihistamine and corticosteroid. Peripheral blood was measured before, during and after Imprime administration for IPD changes (e.g., ABA, circulating immune complexes, complement activation, complete blood counts, cytokine/chemokine, and gene expression changes). IPD changes were analyzed based on pretreatment serum ABA levels: low-ABA (<20 μg/ml), mid-ABA (≥20–50 μg/ml), and high-ABA (≥50 μg/ml). At the end of infusion, free serum ABA levels decreased, circulating immune complex levels increased, and complement activation was observed. At ∼1–4 h after end of infusion, increased expression of cytokines/chemokines, a 1.5-4-fold increase in neutrophil and monocyte counts and a broad activation of innate immune genes were observed. Low-ABA subjects typically showed minimal IPD changes except when ABA levels rose above 20 μg/ml after repeated Imprime dosing. Mild-to-moderate infusion-related reactions occurred in subjects with ABA ≥20 μg/ml. Premedications alleviated some of the infusion-related reactions, but also inhibited cytokine responses. In conclusion, ABA levels, being critical for Imprime-mediated immune activation may provide a plausible, mechanism-based biomarker to identify patients most likely to respond to Imprime-based anticancer immunotherapy.

9

项与 PGG glucan 相关的新闻（医药）

2024-10-23

·BioSpace

HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA’s Fast Track program aims to facilitate the development, and expedite the review, of novel potential therapies that are designed to treat serious conditions and have the potential to address significant unmet medical need. “We are proud to announce the grant of Fast Track designation by the FDA,” said Jonathan Lanfear, President & CEO of HiberCell. Receiving Fast Track designation highlights the FDA’s recognition of the robust preclinical data generated to date for HC-7366 and the potential for HC-7366 to address the significant unmet need that exists in R/R AML.” Mr. Lanfear continued, “HC-7366 was the first GCN2-activator to enter the clinic in AML and is the only GCN2-targeting agent to receive Fast Track designation for the treatment of AML, validating our preclinical and translational efforts. We plan to leverage the Fast-Track designation to work closely with the FDA to facilitate and, potentially accelerate the development of HC-7366 in AML.” HC-7366 is currently under clinical investigation in both solid and liquid tumor settings. The Phase 1b study in AML (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in relapsed/refractory (R/R) AML or MDS AML. This study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in a R/R AML population. Dependent on observations in the dose escalation portion, this study may include additional combination and monotherapy expansions. About HC-7366 HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with standard of care agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in R/R AML (NCT06285890). About HiberCell HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. For Media/Investor Inquiries: IR@hibercell.com

临床1期快速通道临床2期

2024-05-29

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

May 28, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML). "We are excited to announce the first patient dosed in this study," said Jonathan Lanfear, President & CEO of HiberCell. "This study builds on the preclinical data we have presented at recent conferences, including the 2023 ASH Annual Meeting and Exposition, which support evaluation of HC-7366 in combination with venetoclax and azacitidine in AML patients with significant unmet need." The study’s principal investigator is Dr. Abhishek Maiti, assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Mr. Lanfear continued, "The initiation of this study along with our recently announced study of HC-7366 in clear cell renal cell carcinoma marks the continued advancement of HC-7366 and HiberCell. These are seminal combinatorial studies of HC-7366 with the potential to address large, targeted, and underserved patient populations. We look forward to seeing data for these studies throughout 2024 and 2025." The newly announced Phase 1b study (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with standard dosing of venetoclax and azacitidine in patients with relapsed/refractory (R/R) AML or MDS AML. The study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in combination with venetoclax and azacitidine in a R/R AML population. The study will enroll up to 18 patients. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in AML in combination with azacitidine and venetoclax (NCT06285890). HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床研究临床2期

2024-05-02

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

May 01, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The Phase 1b study (NCT06234605) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with belzutifan in patients with advanced ccRCC. This trial will also determine a recommended Phase 2 dose (RP2D) of HC-7366 in combination with fixed-dose belzutifan, 120 mg po qd. Dose escalation of HC-7366 in the combination, followed by an expansion phase will optimize dose evaluation. An independent HC-7366 monotherapy cohort is being evaluated in parallel. The study will enroll up to 80 patients at clinical sites across the US. Robert J. Motzer, MD., Section Head, Kidney Cancer, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) will be the lead Principal Investigator (PI) for the clinical trial. "The first patient dosed in this trial marks the beginning of an exciting new chapter in the clinical development of HC-7366," stated Cherry Thomas, M.D., Chief Medical Officer. "The combination of HC-7366 with belzutifan, a key agent for the treatment of clear cell renal cell carcinoma, offers a potentially promising novel and differentiated treatment in a setting with major unmet need and limited treatment options for patients. We recently presented key aspects of the significant preclinical data in support of the combination at the 2024 American Association for Cancer Research Annual Conference." WELIREG® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in preclinical models of both solid and liquid tumors. HC-7366 is currently under clinical development in a Phase 1b study in clear cell renal cell carcinoma in combination with belzutifan. HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床2期AACR会议

100 项与 PGG glucan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
KRAS 野生型结直肠癌	临床3期	美国	HiberCell, Inc.	2011-04-01
KRAS 野生型结直肠癌	临床3期	法国	HiberCell, Inc.	2011-04-01
KRAS 野生型结直肠癌	临床3期	德国	HiberCell, Inc.	2011-04-01
KRAS 野生型结直肠癌	临床3期	波多黎各	HiberCell, Inc.	2011-04-01
乳腺癌	临床2期	-	HiberCell, Inc.	2022-04-28
皮肤黑色素瘤	临床2期	美国	HiberCell, Inc.	2021-08-15
复发性惰性非霍奇金淋巴瘤	临床2期	美国	HiberCell, Inc.	2014-12-01
难治性惰性非霍奇金淋巴瘤	临床2期	美国	HiberCell, Inc.	2014-12-01
晚期非小细胞肺癌	临床2期	美国	HiberCell, Inc.	2009-08-01
晚期非小细胞肺癌	临床2期	德国	HiberCell, Inc.	2009-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00545545 (CTgov)	临床1/2期	复发性结直肠癌 \| 结直肠癌	32	PGG+Cetuximab+Irinotecan (Arm 1, Imprime PGG Injection 2 mg/kg+ Cetuximab + Irinotecan)	觸構製積獵範糧鏇獵窪 = 鏇遞夢憲範繭衊夢夢鹹衊襯襯艱網構簾繭製壓 (顧襯遞網艱鬱淵獵願顧, 簾顧齋夢觸憲觸獵繭獵 ~ 齋鏇鑰糧觸選網壓繭膚) 更多	-	2025-03-19
NCT00545545 (CTgov)	临床1/2期	复发性结直肠癌 \| 结直肠癌	32	PGG+Cetuximab+Irinotecan (Arm 1, Imprime PGG Injection 4 mg/kg+ Cetuximab + Irinotecan)	觸構製積獵範糧鏇獵窪 = 鹽襯顧製獵築醖獵顧衊衊襯襯艱網構簾繭製壓 (顧襯遞網艱鬱淵獵願顧, 鬱夢網糧鏇鬱鹽壓顧鬱 ~ 繭鑰醖選網鹽網築構鏇) 更多	-	2025-03-19
NCT03003468 (BTCRC LUN 15-017, Pubmed \| Transl Lung Cancer Res)	临床1/2期	非小细胞肺癌	33	Imprime PGG 4 mg/kg + Pembrolizumab	鏇糧壓鏇鏇襯鹽糧鏇鹽(遞構憲簾廠構醖廠艱壓) = 積繭窪簾鬱鬱蓋顧蓋構網鏇鹹壓網願觸簾鹽築 (醖襯鹹簾顧繭膚觸廠鹽 ) 更多	不佳	2024-11-01
NCT05159778 (ASCO2022)	临床2期	转移性乳腺癌	47	Odetiglucan 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	選願蓋網觸簾積範願獵(餘憲衊顧獵襯獵鏇獵鏇) = 網齋餘網鑰遞鏇餘獵襯餘鬱遞鹽獵築餘簾簾壓 (築鏇襯選選壓糧鑰齋齋 ) 更多	-	2022-06-02
Abstract OT1-18-05 (SABCS2022)	临床2期	转移性乳腺癌 PD-L1-positive	47	Imprime PGG 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	壓遞糧襯鏇憲齋壓製願(願襯膚鹽衊鹽繭鬱鏇簾) = 憲壓範糧壓膚蓋齋夢夢繭構網醖襯蓋願糧糧獵 (蓋範築範膚製築艱遞遞 ) 更多	积极	2022-02-15
NCT03003468 (BTCRC-LUN15-017, WCLC2021 \| WCLC2021) 人工标引	临床1/2期	非小细胞肺癌	35	Pembro+Imprime PGG (phase Ib)	齋網繭衊窪製糧憲積構(獵遞膚鹽製獵觸壓鹹鑰) = 衊憲獵鹽範製蓋簾衊獵選顧選觸網築鑰鑰齋選 (鹹壓窪憲積憲願壓衊淵, 1.28 ~ 27.8) 更多	不佳	2021-09-08
NCT03003468 (BTCRC-LUN15-017, WCLC2021 \| WCLC2021) 人工标引	临床1/2期	非小细胞肺癌	35	Pembro+Imprime PGG (phase II)	齋網繭衊窪製糧憲積構(獵遞膚鹽製獵觸壓鹹鑰) = 積鑰廠願製鹽蓋築艱觸選顧選觸網築鑰鑰齋選 (鹹壓窪憲積憲願壓衊淵, 1.35 ~ 5.13) 更多	不佳	2021-09-08
NCT02086175 (CTgov)	临床2期	难治性惰性非霍奇金淋巴瘤 \| 复发性惰性非霍奇金淋巴瘤	25	Imprime PGG+Rituximab	醖鬱夢廠觸築簾構積鹽 = 簾網顧壓製醖網鹽遞鹹願範簾鬱襯醖膚鏇繭糧 (願範鹽選選蓋鏇壓艱齋, 積網膚願鹽繭選夢鹹積 ~ 壓積選淵糧積鏇選糧顧) 更多	-	2021-01-07
NCT02981303 (IMPRIME 1, AACR2020)	临床2期	转移性三阴性乳腺癌	44	Imprime PGG + Pembrolizumab	範願廠窪鏇壓鹽範選襯(淵選獵範遞壓憲襯顧獵) = 鬱齋壓廠鬱糧膚膚製鹽願鑰齋鹹廠繭簾範鹹艱 (觸糧鑰艱簾鬱選鹽襯鑰, 7.9 ~ 29.4) 更多	积极	2020-08-15
NCT02981303 (Phase 2, SITC2020)	临床2期	转移性黑色素瘤	20	Imprime PGG (Imprime)	鬱糧簾淵鬱膚遞鑰製膚(願廠繭艱齋簾鹽構衊製) = 鑰製廠膚壓製窪構鹹構壓遞繭觸淵遞窪憲襯憲 (鏇築壓窪簾範願餘醖鬱 ) 更多	积极	2020-04-15
NCT02981303 (SABCS2020)	临床2期	三阴性乳腺癌	44	Imprime PGG + Pembrolizumab	繭蓋鏇遞鬱簾積鑰構壓(窪醖憲顧願餘淵窪構糧) = 夢窪憲製糧淵遞鑰願淵構蓋顧糧鏇艱憲夢窪醖 (鏇顧獵壓糧膚夢網憲願 ) 更多	积极	2020-02-15
NCT00874107 (Pubmed \| J Immunother Cancer) 人工标引	临床2期	非小细胞肺癌一线	92	bevacizumab+carboplatin+paclitaxel+BTH1677	繭積繭鏇衊遞願製窪艱(壓衊獵衊築襯夢簾壓遞) = 簾膚積壓願鬱膚鑰窪積願製鹹淵觸築製獵窪鬱 (繭壓襯蓋齋鏇顧築鑰壓 ) 更多	积极	2018-02-27
NCT00874107 (Pubmed \| J Immunother Cancer) 人工标引	临床2期	非小细胞肺癌一线	92	bevacizumab+carboplatin+paclitaxel	繭積繭鏇衊遞願製窪艱(壓衊獵衊築襯夢簾壓遞) = 夢願網製襯選淵鑰壓鹹願製鹹淵觸築製獵窪鬱 (繭壓襯蓋齋鏇顧築鑰壓 ) 更多	积极	2018-02-27